Enlivex Therapeutics Ltd ENLV:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 05/03/24 EDT
1.55quote price arrow down-0.07 (-4.32%)
Volume
100
Close
1.62UNCH (UNCH)
Volume
45,694
52 week range
1.15 - 4.59
Loading...
  • Open1.61
  • Day High1.66
  • Day Low1.52
  • Prev Close1.62
  • 52 Week High4.59
  • 52 Week High Date04/03/24
  • 52 Week Low1.15
  • 52 Week Low Date04/15/24

Key Stats

  • Market Cap30.475M
  • Shares Out18.81M
  • 10 Day Average Volume0.14M
  • Dividend-
  • Dividend Yield-
  • Beta1.31
  • YTD % Change-40

KEY STATS

  • Open1.61
  • Day High1.66
  • Day Low1.52
  • Prev Close1.62
  • 52 Week High4.59
  • 52 Week High Date04/03/24
  • 52 Week Low1.15
  • 52 Week Low Date04/15/24
  • Market Cap30.475M
  • Shares Out18.81M
  • 10 Day Average Volume0.14M
  • Dividend-
  • Dividend Yield-
  • Beta1.31
  • YTD % Change-40

RATIOS/PROFITABILITY

  • EPS (TTM)-1.56
  • P/E (TTM)-1.04
  • Fwd P/E (NTM)-1.88
  • EBITDA (TTM)-24.316M
  • ROE (TTM)-66.88%
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date05/06/2024
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Enlivex Therapeutics Ltd

 

Profile

MORE
Enlivex Therapeutics Ltd is an Israel-based clinical stage macrophage reprogramming immunotherapy company developing Allocetra, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. AllocetraTM is a therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute...
Shai Novik
Executive Chairman of the Board
Oren Hershkovitz Ph.D.
Chief Executive Officer
Shachar Shlosberger CPA
Chief Financial Officer
Address
14 Einstein St.
Ness-ziona
7403618
Israel

Top Peers

SYMBOLLASTCHG%CHG
BIVI
BioVie Inc
0.4904-0.0095-1.9004%
FBRX
Forte Biosciences Inc
0.7141+0.0239+3.4628%
EYEN
Eyenovia Inc
1.01+0.07+7.74%
ITRM
Iterum Therapeutics PLC
1.55-0.03-1.90%
UBX
UNITY Biotechnology Inc
1.61-0.02-1.23%